776 related articles for article (PubMed ID: 12764551)
1. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
Drzezga A; Lautenschlager N; Siebner H; Riemenschneider M; Willoch F; Minoshima S; Schwaiger M; Kurz A
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1104-13. PubMed ID: 12764551
[TBL] [Abstract][Full Text] [Related]
2. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.
Hunt A; Schönknecht P; Henze M; Seidl U; Haberkorn U; Schröder J
Psychiatry Res; 2007 Jul; 155(2):147-54. PubMed ID: 17524628
[TBL] [Abstract][Full Text] [Related]
3. [The comparison of the regional cerebral metabolism rate of glucose in Alzheimer's disease with mild cognitive impairment].
Cao Q; Jiang K; Liu Y; Zhang M; Xiao S; Zuo C; Huang H
Zhonghua Yi Xue Za Zhi; 2002 Dec; 82(23):1613-6. PubMed ID: 12667368
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
[TBL] [Abstract][Full Text] [Related]
5. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease.
Encinas M; De Juan R; Marcos A; Gil P; Barabash A; Fernández C; De Ugarte C; Cabranes JA
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1473-80. PubMed ID: 14579086
[TBL] [Abstract][Full Text] [Related]
6. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga A; Grimmer T; Riemenschneider M; Lautenschlager N; Siebner H; Alexopoulus P; Minoshima S; Schwaiger M; Kurz A
J Nucl Med; 2005 Oct; 46(10):1625-32. PubMed ID: 16204712
[TBL] [Abstract][Full Text] [Related]
7. Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease.
Schönknecht OD; Hunt A; Toro P; Guenther T; Henze M; Haberkorn U; Schröder J
Clin EEG Neurosci; 2011 Apr; 42(2):71-6. PubMed ID: 21675596
[TBL] [Abstract][Full Text] [Related]
8. The reduction of baseline serotonin 2A receptors in mild cognitive impairment is stable at two-year follow-up.
Marner L; Knudsen GM; Madsen K; Holm S; Baaré W; Hasselbalch SG
J Alzheimers Dis; 2011; 23(3):453-9. PubMed ID: 21098981
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
[TBL] [Abstract][Full Text] [Related]
10. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
11. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
[TBL] [Abstract][Full Text] [Related]
12. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
Mosconi L; Perani D; Sorbi S; Herholz K; Nacmias B; Holthoff V; Salmon E; Baron JC; De Cristofaro MT; Padovani A; Borroni B; Franceschi M; Bracco L; Pupi A
Neurology; 2004 Dec; 63(12):2332-40. PubMed ID: 15623696
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of mild cognitive impairment tending to convert into Alzheimer's disease or dementia with Lewy bodies: A follow-up study in a memory clinic.
Kondo D; Ota K; Kasanuki K; Fujishiro H; Chiba Y; Murayama N; Sato K; Hirayasu Y; Arai H; Iseki E
J Neurol Sci; 2016 Oct; 369():102-108. PubMed ID: 27653873
[TBL] [Abstract][Full Text] [Related]
14. Impaired cerebral glucose metabolism in prodromal Alzheimer's disease differs by regional intensity normalization.
Küntzelmann A; Guenther T; Haberkorn U; Essig M; Giesel F; Henze R; Schroeter ML; Schröder J; Schönknecht P
Neurosci Lett; 2013 Feb; 534():12-7. PubMed ID: 23182881
[TBL] [Abstract][Full Text] [Related]
15. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.
Furukawa K; Okamura N; Tashiro M; Waragai M; Furumoto S; Iwata R; Yanai K; Kudo Y; Arai H
J Neurol; 2010 May; 257(5):721-7. PubMed ID: 19946781
[TBL] [Abstract][Full Text] [Related]
16. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
[TBL] [Abstract][Full Text] [Related]
17. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
18. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.
Mosconi L; Tsui WH; De Santi S; Li J; Rusinek H; Convit A; Li Y; Boppana M; de Leon MJ
Neurology; 2005 Jun; 64(11):1860-7. PubMed ID: 15955934
[TBL] [Abstract][Full Text] [Related]
19. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism.
Pappatà S; Santangelo G; Aarsland D; Vicidomini C; Longo K; Bronnick K; Amboni M; Erro R; Vitale C; Caprio MG; Pellecchia MT; Brunetti A; De Michele G; Salvatore M; Barone P
Neurology; 2011 Oct; 77(14):1357-62. PubMed ID: 21940621
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
